CARsgen Therapeutics Holdings Limited (HKG:2171)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
22.90
-0.10 (-0.43%)
Aug 19, 2025, 9:43 AM HKT
-0.43%
Market Cap12.74B
Revenue (ttm)92.10M
Net Income (ttm)-572.06M
Shares Out553.81M
EPS (ttm)-1.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,284,600
Average Volume2,493,371
Open23.00
Previous Close23.00
Day's Range22.66 - 23.22
52-Week Range2.48 - 25.60
Beta0.51
RSI55.33
Earnings DateAug 22, 2025

About HKG:2171

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junct... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 465
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2171
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.